US/UK/Canada

Share

Pick a time period -
Tags ( Active)

XYMOGEN Receives SMART Award for Corporate Excellence in Health Care and Life Sciences Industry

ORLANDO, Fla. — May 21, 2013 — Orlando-based nutraceutical company XYMOGEN announced today that it is the recipient of the 2013 SMART award for corporate excellence in the health care and life sciences industry from the Orlando chapter of the Association for Corporate Growth (ACG). XYMOGEN is a family-owned, health-sciences company that researches, develops, and manufactures high-quality prescription medical foods and nutraceuticals available exclusively through doctors, pharmacists and other health care providers. ACG Orlando presents the annual SMART awards to recognize companies

XYMOGEN identifies allergen oversight by third-party manufacturer; issues recall of artriphen™

ORLANDO, Fla. — May 1, 2013 — Nutraceutical company XYMOGEN in Orlando, Fla., is recalling artriphen, a product recommended for the support of healthy joint function, because it contains traces of the undeclared allergens soy and milk. People who have an allergy or severe sensitivity to either allergen run the risk of serious or life-threatening allergic reaction if they consume this product. Although there have been no reported allergic reactions or any adverse events in connection with the product to date, consumers are urged to return this product for a full refund. XYMOGEN learned

XYMOGEN RECEIVES GOLD STANDARD FOR SAFETY, QUALITY IN MANUFACTURING

ORLANDO, Fla. — March 7, 2013 — Orlando-based nutraceutical company XYMOGEN announced today that its manufacturing facility has earned the prestigious NSF International Good Manufacturing Practices (GMP) and GMP for Sport Athletic Banned Substances Program registrations. The GMP registration verifies that XYMOGEN has the proper methods, equipment, facilities and controls in place to produce dietary supplements. Those manufacturing practices were developed in accordance with the U.S. Food and Drug Administration’s (FDA) regulations on dietary manufacturing, packaging and distribution.

XYMOGEN PASSES $5 MILLION MONTHLY SALES MILESTONE FOR JANUARY

CORRECTION  — ORLANDO, Fla. — Feb. 8, 2013 — Orlando-based health sciences company XYMOGEN reported more than $5.2 million in sales for January, a record for the company. “That’s $2 million more than in January 2012 and $1 million more than we’ve ever done in any one month,” said Mike Mahoney, senior vice president at XYMOGEN. “We started off this month very, very big. ... We’re averaging $237,301 a day in sales.” Mahoney says the month’s sales exceeded projections of $4 million. October sales were $4.2 million. “The vast majority of January’s growth may be attributed to the

XYMOGEN SUBSIDIARY PHARMACEUTIX MEDICAL FOODS ANNOUNCES DUCK WILLIAMS AS VICE PRESIDENT

Orlando, Fla. – Thursday, November 15, 2012 – Pharmaceutix Medical Foods, a wholly owned subsidiary of XYMOGEN, announced today that Duck Williams has been named Vice President of the company. Williams has more than 25 years of experience in the pharmaceutical industry and was previously a sales manager for Pamlab LLC for almost 15 years. During his time at Pamlab, the company was one of the first to market medical food products on a larger, national scale. “Many medical foods have been shown to be therapeutic and actually help treat the disease causation of certain diseases and

XYMOGEN Opens Global Headquarters/ New Manufacturing Center And Is Recognized Fifth Time By Inc. Magazine

Family-owned health sciences company opens new international location in Florida and is ranked again by Inc. Magazine as one of America’s fastest growing companies.ORLANDO, Fla. – Wednesday, September 19, 2012 – XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Florida, has officially opened the doors to its high-tech global headquarters and manufacturing facility . At the same time, Inc. Magazine has ranked the company for the fifth time as one of America’s top 5,000 fastest growing private businesses. XYMOGEN founder Brian Blackburn says he’s doubly proud of

XYMOGEN HOSTS GRAND OPENING OF ITS GLOBAL HEADQUARTERS/NEW MANUFACTURING CENTER AND GETS RECOGNIZED FIFTH TIME BY INC. MAGAZINE

Family-owned health sciences company opens new international location in Orlando and is ranked again by Inc. Magazine as one of nation’s fastest growing companies.ORLANDO, Fla. – Tuesday, September 11, 2012 – XYMOGEN, a family-owned, health sciences company headquartered in Orlando, will officially open the doors this week to its high-tech global headquarters and manufacturing facility located south of downtown. At the same time, Inc. Magazine ranked the company for the fifth time as one of the nation’s top 5,000 fastest growing private businesses. XYMOGEN founder Brian Blackburn says he’

XYMOGEN Releases HistDAO For Histamine-Related Digestive System Issues

ORLANDO, Fla. – Thursday, August 16, 2012 – Health sciences leader XYMOGEN announces the release of HistDAO, an exclusive dietary supplement that aids in issues associated with intestinal or negative intolerance to food-derived histamines.* HistDAO, which is the new name for HistoXYM, supports the healthy degradation of food-derived histamines in the lower intestines.* Diamine Oxidase (DAO) is the main enzyme associated with metabolizing ingested histamines from foods such as tuna, aged cheese, tomatoes, red wine or champagne. Digestive issues are becoming more common and more

XYMOGEN Launches Pharmaceutix™ Medical Foods Division and Partners with Acasti Pharma to Bring Revolutionary Medical Food to United States and Beyond

ORLANDO, Fla. – Wednesday, July 11, 2012 – XYMOGEN announced today an exclusive partnership with Acasti Pharma, the biopharmaceutical company with whom they will launch the worldwide distribution of LipiChol540™, a physician-prescribed medical food to manage omega-3 phospholipid deficiency. The formula will be distributed by Pharmaceutix Medical Foods, a wholly owned subsidiary of XYMOGEN. Acasti, which is headquartered in Canada, was the first to discover the effects of phospholipids, a major component of cell membranes essential for all vital cell processes. The company is a pioneer in

XYMOGEN REPORTS RECORD ACTIVITIES FOR Q1-2012 INCLUDING REVENUES, EDUCATIONAL DEVELOPMENT, SPONSORSHIPS AND NEW MANUFACTURING HEADQUARTERS

Dr. John Brimhall joins XYMOGEN as Director of Educational Development XYMOGEN Assumes Alternative Medicine Review Corporate Sponsorship Move to new 136,000 sq.ft. Manufacturing Headquarters set for April 30thORLANDO, Fla. – Monday, April 16, 2012 – Orlando-based company XYMOGEN today reported financial results for its first quarter FY-2012.  Q1-2012 Financial Highlights · XYMOGEN posted Q1-2012 revenues / earnings of $11.3 million / $151K compared to $9.4 million /$696K for Q1-2011.  This represents a 21 percent period-over-period revenue growth and exceeded the company’s

Nationally Recognized Chiropractor Joins XYMOGEN To Educate Doctors Around The World

ORLANDO, Fla. – Tuesday, April 10, 2012 – A pioneer in chiropractic healthcare, Dr. John Brimhall has joined the XYMOGEN Medical Board of Advisors as Director of Educational Development. After training thousands of doctors across the country, he will now also provide continuing education training to XYMOGEN’s worldwide network of practitioners. Dr. Brimhall’s innovative patient evaluation and treatment methods, used by chiropractors and other physicians across the country, have earned him the nickname of “Father of Wellness in Chiropractic” by American Chiropractor Magazine. He has

XYMOGEN REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2011

Q4-2011 Closing of $14.34 Million in Building and Equipment FinancingORLANDO, Fla. – Wednesday, February 22, 2012 – Orlando-based company XYMOGEN today reported financial results for its fiscal year ended Dec. 31, 2011. Fiscal Year 2011 Financial Highlights ·     XYMOGEN achieved revenue of $39.5 million compared to $32.6 million in fiscal year 2010. This represents a 21 percent year-over-year growth and exceeded the company’s target of 15 percent growth projected at the outset of the year. ·     Net income was $1.55 million for fiscal 2011, compared to $1.6 million for fiscal 2010.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media